Ron Bentsur - Net Worth and Insider Trading
Ron Bentsur Net Worth
The estimated net worth of Ron Bentsur is at least $24 Million dollars as of 2024-05-16. Ron Bentsur is the Chairman & CEO, 10% Owner of Nuvectis Pharma Inc and owns about 3,246,424 shares of Nuvectis Pharma Inc (NVCT) stock worth over $22 Million. Ron Bentsur is the CEO of Keryx Biopharmaceuticals Inc and owns about 777,209 shares of Keryx Biopharmaceuticals Inc (KERX) stock worth over $3 Million. Ron Bentsur is also the Director of Beyond Air Inc and owns about 144,736 shares of Beyond Air Inc (XAIR) stock worth over $173,683. Besides these, Ron Bentsur also holds Stemline Therapeutics Inc (STML) . Details can be seen in Ron Bentsur's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Ron Bentsur has not made any transactions after 2024-05-14 and currently still holds the listed stock(s).
Transaction Summary of Ron Bentsur
Ron Bentsur Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Ron Bentsur owns 6 companies in total, including Beyond Air Inc (XAIR) , Stemline Therapeutics Inc (STML) , and UroGen Pharma Ltd (URGN) among others .
Click here to see the complete history of Ron Bentsur’s form 4 insider trades.
Insider Ownership Summary of Ron Bentsur
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
XAIR | Beyond Air Inc | 2023-03-20 | director |
STML | Stemline Therapeutics Inc | 2020-06-10 | director |
URGN | UroGen Pharma Ltd | 2019-01-01 | director & Chief Executive Officer |
2015-04-06 | director & Chief Executive Officer | ||
2006-08-17 | CEO | ||
2024-05-14 | director & Chairman & CEO |
Ron Bentsur Latest Holdings Summary
Ron Bentsur currently owns a total of 4 stocks. Among these stocks, Ron Bentsur owns 3,246,424 shares of Nuvectis Pharma Inc (NVCT) as of May 14, 2024, with a value of $22 Million and a weighting of 88.26%. Ron Bentsur owns 777,209 shares of Keryx Biopharmaceuticals Inc (KERX) as of April 6, 2015, with a value of $3 Million and a weighting of 10.68%. Ron Bentsur also owns 144,736 shares of Beyond Air Inc (XAIR) as of March 20, 2023, with a value of $173,683 and a weighting of 0.71%. The other 1 stocks Stemline Therapeutics Inc (STML) have a combined weighting of 0.35% among all his current holdings.
Latest Holdings of Ron Bentsur
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
NVCT | Nuvectis Pharma Inc | 2024-05-14 | 3,246,424 | 6.65 | 21,588,720 |
KERX | Keryx Biopharmaceuticals Inc | 2015-04-06 | 777,209 | 3.36 | 2,611,422 |
XAIR | Beyond Air Inc | 2023-03-20 | 144,736 | 1.20 | 173,683 |
STML | Stemline Therapeutics Inc | 2015-03-18 | 7,285 | 11.83 | 86,182 |
Holding Weightings of Ron Bentsur
Ron Bentsur Form 4 Trading Tracker
According to the SEC Form 4 filings, Ron Bentsur has made a total of 41 transactions in Nuvectis Pharma Inc (NVCT) over the past 5 years, including 41 buys and 0 sells. The most-recent trade in Nuvectis Pharma Inc is the acquisition of 1,940 shares on May 14, 2024, which cost Ron Bentsur around $13,076.
According to the SEC Form 4 filings, Ron Bentsur has made a total of 0 transactions in Keryx Biopharmaceuticals Inc (KERX) over the past 5 years. The most-recent trade in Keryx Biopharmaceuticals Inc is the sale of 1,592 shares on April 6, 2015, which brought Ron Bentsur around $18,595.
According to the SEC Form 4 filings, Ron Bentsur has made a total of 20 transactions in Beyond Air Inc (XAIR) over the past 5 years, including 1 buys and 19 sells. The most-recent trade in Beyond Air Inc is the acquisition of 2,300 shares on March 20, 2023, which cost Ron Bentsur around $14,904.
More details on Ron Bentsur's insider transactions can be found in the Insider Trading History of Ron Bentsur table.Insider Trading History of Ron Bentsur
- 1
Ron Bentsur Trading Performance
GuruFocus tracks the stock performance after each of Ron Bentsur's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ron Bentsur is 19.85%. GuruFocus also compares Ron Bentsur's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ron Bentsur within 3 months outperforms 15 times out of 43 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Ron Bentsur's insider trading performs compared to the benchmark.
Performance of Ron Bentsur
Ron Bentsur Ownership Network
Ownership Network List of Ron Bentsur
Ownership Network Relation of Ron Bentsur
Ron Bentsur Owned Company Details
What does Beyond Air Inc do?
Who are the key executives at Beyond Air Inc?
Ron Bentsur is the director of Beyond Air Inc. Other key executives at Beyond Air Inc include director & President & CEO Amir Avniel , Chief Medical Officer Jeff Lynn Myers , and Chief Operating Officer Michael A. Gaul .
Beyond Air Inc (XAIR) Insider Trades Summary
Over the past 18 months, Ron Bentsur made 1 insider transaction in Beyond Air Inc (XAIR) with a net purchase of 2,300. Other recent insider transactions involving Beyond Air Inc (XAIR) include a net purchase of 1,682,837 shares made by Robert Carey , a net purchase of 89,179 shares made by Steven A. Lisi , and a net purchase of 19,000 shares made by Michael A. Gaul .
In summary, during the past 3 months, insiders sold 0 shares of Beyond Air Inc (XAIR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 77,019 shares of Beyond Air Inc (XAIR) were sold and 1,858,027 shares were bought by its insiders, resulting in a net purchase of 1,781,008 shares.
Beyond Air Inc (XAIR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Beyond Air Inc Insider Transactions
Ron Bentsur Mailing Address
Above is the net worth, insider trading, and ownership report for Ron Bentsur. You might contact Ron Bentsur via mailing address: 750 Lexington Ave, 20th Fl, New York Ny 10022.